FENC
Fennec Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.95
+0.74%Year over year
Reported trailing growth
- Revenue
- +77.8%
- EBITDA
- +72.6%
- EBIT
- +88.0%
- EPS
- +70.8%
- Free cash flow
- +82.5%
- Operating cash flow
- +82.5%
Forward estimates
Based on analyst estimates
- Revenue
- +58.9%
- EBITDA
- +1542.7%
- EPS
- +663.6%
Three-year CAGR
- Revenue
- +207.5%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026